It would have been interesting to have sat in on the senior management meetings at Merck that thrashed out the Organon ...

JERSEY CITY, N.J., April 01, 2025--Organon announced it has acquired regulatory and commercial rights in the U.S. for TOFIDENCE™, a biosimilar to ACTEMRA®, for intravenous infusion. JERSEY CITY ...

Potential Organon & Co. (NYSE:OGN) shareholders may wish to note that the CEO & Director, Kevin Ali, recently bought US$299k worth of stock, paying US$8.81 for each share. That's a very solid buy ...

Looking at the universe of stocks we cover at Dividend Channel, on 5/12/25, H2O America (Symbol: HTO), Exelon Corp (Symbol: EXC), and Organon & Co (Symbol: OGN) will all trade ex-dividend for ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

The intravenous biosimilar of IL-6 inhibitor Actemra (tocilizumab) – called Tofidence (formerly BIIB800) – has been cleared for three of the indications for which Roche’s drug is used ...

Story April 9 - Organon: The women’s health drugmaker is initiating New Jersey layoffs that will hit 93 staffers. The company is undergoing a revamp and has been reducing its headcount in ...

Copyright © 2025 MarketWatch, Inc. All rights reserved.